MeSH term
Frequency | Condition_Probility | Female | 14 | 0.0 |
Humans | 58 | 0.0 |
Mutation | 4 | 0.0 |
Binding Sites | 4 | 0.0 |
Kinetics | 7 | 0.0 |
Research Support, Non-U.S. Gov't | 34 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Substrate Specificity | 7 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Animals | 35 | 0.0 |
Carcinogens | 2 | 2.0 |
Hyperplasia | 4 | 1.0 |
Keratin/genetics | 5 | 11.0 |
Mice | 18 | 0.0 |
Mice, Transgenic | 10 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 21 | 0.0 |
Tetradecanoylphorbol Acetate | 2 | 2.0 |
Amino Acid Sequence | 12 | 0.0 |
Hydrolysis | 6 | 0.0 |
Molecular Sequence Data | 21 | 0.0 |
Tissue Kallikreins/*metabolism | 2 | 40.0 |
Adult | 3 | 0.0 |
Aged | 2 | 0.0 |
Base Sequence | 13 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Introns | 2 | 0.0 |
Male | 17 | 0.0 |
Middle Aged | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Linear Models | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Mice, Inbred ICR | 3 | 1.0 |
Mice, Knockout | 2 | 0.0 |
Transforming Growth Factor alpha/*genetics | 2 | 4.0 |
Cell Division/genetics | 2 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 3 | 1.0 |
DNA Primers | 3 | 0.0 |
*Genes, ras | 3 | 1.0 |
Chromosome Mapping | 9 | 0.0 |
Cattle | 3 | 0.0 |
Comparative Study | 6 | 0.0 |
Fluorescent Dyes/metabolism | 2 | 2.0 |
Peptide Fragments/metabolism | 2 | 0.0 |
Species Specificity | 2 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Rats | 8 | 0.0 |
Rats, Wistar | 2 | 0.0 |
*Genes, fos | 2 | 3.0 |
Hexokinase/*genetics | 6 | 40.0 |
Isoenzymes/genetics | 2 | 0.0 |
Pregnancy | 2 | 0.0 |
Bradykinin/metabolism | 3 | 21.0 |
Tissue Kallikreins | 5 | 10.0 |
Cross Reactions | 2 | 0.0 |
Kallikreins/*metabolism | 3 | 18.0 |
Caspases/metabolism | 2 | 0.0 |
Cell Line, Tumor | 5 | 0.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Enzyme Activation | 3 | 0.0 |
Prostate-Specific Antigen/*metabolism | 2 | 9.0 |
Rabbits | 2 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Age Factors | 2 | 0.0 |
Cohort Studies | 2 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Genome, Human | 2 | 0.0 |
Hexokinase/genetics | 2 | 50.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Receptors, Interleukin-2/genetics | 2 | 5.0 |
Animals, Newborn | 3 | 0.0 |
Phenotype | 3 | 0.0 |
Transgenes | 2 | 0.0 |
Blotting, Western | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Hamsters | 4 | 0.0 |
Time Factors | 4 | 0.0 |
Cell Division/drug effects | 2 | 0.0 |
Epidermis/*metabolism/pathology | 2 | 40.0 |
Genes, ras | 2 | 0.0 |
Transforming Growth Factor alpha/*biosynthesis/genetics | 2 | 12.0 |
Phosphorylation | 3 | 0.0 |
Transfection | 2 | 0.0 |
Papilloma/*genetics/pathology | 2 | 50.0 |
Cell Differentiation | 3 | 0.0 |
Cell Survival | 2 | 0.0 |
Light | 2 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Mice, Nude | 2 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Oxygen/metabolism | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
Apoptosis | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Fibroblasts/enzymology | 2 | 1.0 |
Hybrid Cells | 2 | 0.0 |
Potassium Channels/*genetics | 2 | 1.0 |
*Chromosomes, Human, Pair 10 | 3 | 1.0 |
Brain/*enzymology | 2 | 1.0 |
Molecular Weight | 2 | 0.0 |
*Cloning, Molecular | 2 | 0.0 |
*Chromosome Mapping | 4 | 0.0 |
*Genes, Structural | 2 | 0.0 |
Erythrocytes/*enzymology | 5 | 0.0 |
Genetic Markers | 2 | 0.0 |
Hexokinase/blood/*genetics | 2 | 66.0 |
Infant | 3 | 0.0 |
*Trisomy | 5 | 4.0 |
*Chromosomes, Human, 6-12 and X | 7 | 5.0 |
Karyotyping | 4 | 0.0 |
Abnormalities, Multiple/genetics | 3 | 3.0 |
Dermatoglyphics | 2 | 16.0 |
English Abstract | 3 | 0.0 |
Mental Retardation/genetics | 4 | 3.0 |
Infant, Newborn | 2 | 0.0 |
Erythrocytes/enzymology | 2 | 0.0 |
Hexokinase/*blood | 2 | 40.0 |
